Financial Services

  A few days ago, I shared a list, a much smaller list, of unicorn companies that sit in the healthcare and biotechnology industries. To refresh your memory, a unicorn is a technology-related organization with a valuation of more than $1 billion, typically a start-up, and with no real track record of success. In a recent report, […]

  Perficient’s Life Sciences practice regularly monitors the software release notes for several Oracle Health Sciences applications, as well as our own clinical and safety systems. The systems covered in our review are: 

  Have you heard? Some retail establishments, in countries like the Netherlands, don’t accept cash anymore. As I mentioned in a previous post, digital money is making big waves – everywhere. While it’s starting to make a serious dent in the United States, the use of mobile payments are much more widespread in other countries. […]

  Several days ago, I wrote about how the life sciences industry, including government organizations, is struggling when it comes to the reporting of clinical trial results to the ClinicalTrials.gov database. Unfortunately, other issues plague the industry, including one that The New York Times reported on January 14, 2016. The Government Accountability Office (GAO) found […]

  The life sciences industry could learn a little something from Southwest Airlines’ “Transfarency” campaign, in terms of reporting clinical trial results. A recent investigation by the publication STAT found significant violations in the reporting of clinical trial results to the ClinicalTrials.gov database. Most academic research institutions, drug companies, and even the National Institutes of […]

  An interesting thing happened in pharma and investing. It involved Regeneron and their July 24, 2015 FDA-approved cholesterol drug, Praluent. Forbes outlined the situation, which caused Regeneron stock to drop significantly, in a January 6, 2016 article. According to Matthew Herper, a Forbes columnist, investors got a hold of data from the FDA’s Adverse […]

  Last week, I wrote that Vice President Joe Biden was going to meet with cancer researchers to talk about regulatory questions revolving around precision medicine. Today, we know much more about the cancer “moonshot” President Obama charged Biden with in this week’s State of the Union address. In a post on the publishing platform […]

  We’ve been getting a lot of requests, lately, to help companies decommission their old GxP systems. The systems were once validated and still contain GxP data that might someday need to be reviewed or analyzed, but they’re no longer being actively used. They’re just sitting there, taking up server space, undergoing basic IT maintenance, […]

  I really don’t like carrying cash. And, the only reason I do is because that’s all my barber accepts. I prefer using digital money. Huh, digital money? According to Investopedia, digital money is “any means of payment that exists purely in electronic form.” In other words, think of digital money as using any payment […]

  According to STAT, Vice President Joe Biden is meeting with over a dozen of the nation’s top cancer researchers today to talk about regulatory questions revolving around precision medicine. As you might recall, Biden’s son, Beau, recently died of brain cancer at the age of 46. 

  On December 17, 2015, the FDA issued a warning letter to Sun Pharmaceuticals Industries Ltd. in Gujarat, India. Sun Pharma’s website boasts that it is the “World’s 5th Largest Specialty Generic Pharmaceutical Company” with over 2,000 products in more than 150 markets across the globe. When an organization that large winds up with a […]

  Welcome to the New Year! Similar to the way we share our most popular blog posts on a monthly basis, it only makes sense to look back at the most viewed posts from 2015. So, here it goes, with number one being the most read piece.